After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
TheStreet’s Chris Versace and Bob Lang said biotech companies like Celgene (CELG) are slowly but surely staging a quiet resurgence.
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
Trade-Ideas LLC identified Celgene (CELG) as a strong on high relative volume candidate
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.